Cyclin-dependent-kinase-inhibitors - Pipeline Insight, 2022

“Cyclin-dependent-kinase-inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Cyclin-dependent-kinase-inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Cyclin-dependent-kinase-inhibitors Understanding

Cyclin-dependent-kinase-inhibitors: Overview

Cyclin-dependent kinases (CDKs) are a family of enzymes-serine threonine kinases - that, under normal physiological conditions, play significant roles in controlling cell-cycle progression and transcription regulation. Overexpression of some CDKs and their associated cyclins, as well as downregulation of CDK inhibitors (CKIs), can lead to abnormal cellular proliferation and cancer progression. Due to such dysregulation of CDKs in many cancers, targeting of this family of enzymes has emerged as a promising strategy in the treatment of multiple cancer types, including blood and solid tumours. Targeting the cell cycle via the CDK4/6-Rb axis has proven the most successful approach in the clinic to date. The FDA has approved the CDK4/6 inhibitors palbociclib, abemaciclib and ribociclib as treatments for hormone receptor-positive (HR+) metastatic breast cancer (mBC), in combination with endocrine therapy.

""Cyclin-dependent-kinase-inhibitors - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cyclin-dependent-kinase-inhibitors pipeline landscape is provided which includes the disease overview and Cyclin-dependent-kinase-inhibitors treatment guidelines. The assessment part of the report embraces, in depth Cyclin-dependent-kinase-inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cyclin-dependent-kinase-inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Cyclin-dependent-kinase-inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Cyclin-dependent-kinase-inhibitors.

Cyclin-dependent-kinase-inhibitors Emerging Drugs Chapters

This segment of the Cyclin-dependent-kinase-inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cyclin-dependent-kinase-inhibitors Emerging Drugs
• SHR6390: Jiangsu Hengrui Medicine Co.

SHR-6390 acts as inhibitors of Cyclin-dependent kinase 4 and Cyclin-dependent kinase 6. It is being developed by Jiangsu Hengrui Medicine for the treatment of Breast cancer.
• GB491 (lerociclib): Genor Pharma

GB491 (lerociclib) is a potent, selective, potentially best-in-class oral CDK4/6 for HR+/HER2-breast cancer in China. GB491 has consistently demonstrated efficacy in several pre-clinical models and clinical trials in HR+/HER2-breast cancer. CDK4/6 inhibitors in combination with fulvestrant represent an established treatment for HR+/HER2- advanced or metastatic breast cancer and have demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS). Preliminary results of clinical trials indicate that GB491 has a differentiated PK and tolerability profile from other CDK4/6 inhibitors, allowing for continuous dosing with fewer dose-limiting toxicities such as neutropenia and less complete blood count monitoring. Lerociclib is currently undergoing a Phase IIa clinical trial conducted by licensing partner, G1 Therapeutics.

Further product details are provided in the report……..

Cyclin-dependent-kinase-inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Cyclin-dependent-kinase-inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Cyclin-dependent-kinase-inhibitors

There are approx. 40+ key companies which are developing the therapies for Cyclin-dependent-kinase-inhibitors. The companies which have their Cyclin-dependent-kinase-inhibitors drug candidates in the most advanced stage, i.e. Pre-registration include, Jiangsu Hengrui Medicine Co.
• Phases

DelveInsight’s report covers around 40+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Cyclin-dependent-kinase-inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cyclin-dependent-kinase-inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cyclin-dependent-kinase-inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cyclin-dependent-kinase-inhibitors drugs.

Cyclin-dependent-kinase-inhibitors Report Insights
• Cyclin-dependent-kinase-inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cyclin-dependent-kinase-inhibitors Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Cyclin-dependent-kinase-inhibitors drugs?
• How many Cyclin-dependent-kinase-inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cyclin-dependent-kinase-inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cyclin-dependent-kinase-inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cyclin-dependent-kinase-inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Syros Pharmaceuticals
• Jiangsu Hengrui Medicine
• Aucentra Therapeutics
• Nuvation Bio
• MEI Pharma
• Vincerx Pharma
• Chordia Therapeutics
• Genor Pharma

Key Products
• SY-5609
• SHR-6390
• Auceliciclib
• AU2-94
• AU14-5
• AU2-85
• AU4-53
• NUV-422
• Voruciclib
• VIP-152
• CRD-1835439
• GB491